Suppr超能文献

新型脂质制剂增强了难溶性模型药物吡罗昔康的体外溶出度和通透性特征。

Novel lipid-based formulations enhancing the in vitro dissolution and permeability characteristics of a poorly water-soluble model drug, piroxicam.

作者信息

Prabhu Sunil, Ortega Maru, Ma Chan

机构信息

College of Pharmacy, Western University of Health Sciences, Pomona, CA 91766, USA.

出版信息

Int J Pharm. 2005 Sep 14;301(1-2):209-16. doi: 10.1016/j.ijpharm.2005.05.032.

Abstract

Lipid-based delivery systems are becoming increasingly popular as carriers of drugs due to their ability to overcome barriers to oral absorption. The purpose of this study was to prepare novel lipid-based formulations of a model drug, piroxicam (PXCM), a poorly water-soluble non-steroidal anti-inflammatory drug (NSAID) using 1,2-dimyristoyl-sn-glycero-3-phosphatidylcholine (DMPC) phospholipid alone, and in combination with polyethylene glycol (PEG 4600). Lipid-based drug delivery systems were prepared using conventional methods of preparation and the following aspects were evaluated (1) in vitro dissolution behavior, (2) absorption via Caco-2 cell monolayers and (3) stability of formulations over a 12-month period. In addition, physical characterization studies using differential scanning calorimetry (DSC) were also performed. Formulations of PXCM were prepared using DMPC in the following combinations (A) 1:1 and (B) 2:1 and a mixture of DMPC and PEG 4600 (C) 2:1:1, respectively. Dissolution studies conducted in phosphate buffered saline (PBS, pH 7.4, 37+/-0.5 degrees C) using the USP type II (paddle) dissolution apparatus showed an increase in dissolution rate and extent of the PXCM from all solid dispersion formulations when compared to the control. As such, the rate of drug release was observed to be fastest with formulation (C) showing the greatest increase of over two-fold compared to the control. Release of PXCM from formulations (A) and (B) was intermediate with the latter showing superior dissolution behavior despite containing lower amounts of the carrier lipid than the former. This observation indicates a possible existence of threshold levels for phospholipids carriers beyond which dissolution could be adversely affected. DSC studies further confirmed the dissolution behavior of these formulations demonstrating different levels of amorphous to crystalline nature. Results of HPLC analysis from Caco-2 cell culture studies showed increase in transport of PXCM from all formulations, with formulation (C) showing the maximum increase followed by formulations (B) and (A), when compared to control. The apparent permeability coefficients (Papp) were calculated to be 7.92x10(-6), 9.48x10(-6), 9.2x10(-6) and 5.6x10(-6)cm/s for formulations (A)-(C) and control, respectively. Overall, permeation appeared to improve for all formulations over the control. Stability studies at various temperatures showed all formulations to have good stability for the first 6 months; then a decline in dissolution rates was observed, especially for PEG-based lipid carrier systems, attributed to the increase in crystalline content of the solid dispersions upon storage.

摘要

基于脂质的给药系统作为药物载体正变得越来越受欢迎,因为它们能够克服口服吸收的障碍。本研究的目的是制备一种模型药物吡罗昔康(PXCM)的新型脂质制剂,吡罗昔康是一种水溶性差的非甾体抗炎药(NSAID),单独使用1,2 - 二肉豆蔻酰 - sn - 甘油 - 3 - 磷脂酰胆碱(DMPC)磷脂,并与聚乙二醇(PEG 4600)联合使用。使用常规制备方法制备基于脂质的药物递送系统,并评估以下方面:(1)体外溶出行为,(2)通过Caco - 2细胞单层的吸收,以及(3)制剂在12个月期间的稳定性。此外,还进行了使用差示扫描量热法(DSC)的物理表征研究。PXCM制剂分别使用DMPC按以下组合制备:(A)1:1和(B)2:1,以及DMPC和PEG 4600的混合物(C)2:1:1。使用美国药典II型(桨)溶出装置在磷酸盐缓冲盐水(PBS,pH 7.4,37±0.5℃)中进行的溶出研究表明,与对照相比,所有固体分散体制剂中PXCM的溶出速率和程度均有所增加。因此,观察到制剂(C)的药物释放速率最快,与对照相比增加了两倍多。制剂(A)和(B)中PXCM的释放处于中间水平,尽管后者含有比前者更低量的载体脂质,但其显示出更好的溶出行为。这一观察结果表明磷脂载体可能存在阈值水平,超过该水平溶出可能会受到不利影响。DSC研究进一步证实了这些制剂的溶出行为,表明其具有不同程度的非晶态到晶态性质。来自Caco - 2细胞培养研究的HPLC分析结果表明,与对照相比,所有制剂中PXCM的转运均增加,制剂(C)增加最多,其次是制剂(B)和(A)。计算制剂(A) - (C)和对照的表观渗透系数(Papp)分别为7.92×10(-6)、9.48×10(-6)、9.2×10(-6)和5.6×10(-6)cm/s。总体而言,所有制剂的渗透似乎都比对照有所改善。在不同温度下的稳定性研究表明,所有制剂在最初6个月具有良好的稳定性;然后观察到溶出速率下降,特别是对于基于PEG的脂质载体系统,这归因于储存后固体分散体结晶含量的增加。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验